MedTrace Logo

A Study to Compare LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration（wAMD）

NCT04572698 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 416

Last updated 2020-10-01

No results posted yet for this study

Summary

A randomized, double-blind, parallel controlled, multicenter clinical trial to compare the efficacy and safety of LY09004 and EYLEA in the Treatment of Wet Age-related Macular Degeneration（wAMD)

Conditions

  • Age Related Macular Degeneration

Interventions

DRUG

LY09004

LY09004 injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.

DRUG

Eylea

EYLEA injection by intraocular injection on Day1, Day29, Day57,Day113, Day169, Day225, Day281 and Day337.

Sponsors & Collaborators

  • Shan Dong Boan Biotechnology Co., Ltd(Co-sponsor)

    collaborator UNKNOWN

  • Luye Pharma Group Ltd.

    lead INDUSTRY

Principal Investigators

  • Youxin Chen · Peking Union Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-30
Primary Completion
2023-06-30
Completion
2023-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04572698 on ClinicalTrials.gov